On May 28, the FDA issued the draft guidance, “Contract Manufacturing Arrangements for Drugs: Quality Agreements.” According to an FDA statement, the guidance “describe[s] how parties involved in the contract manufacturing of drugs can utilize Quality Agreements to delineate their responsibilities and assure drug quality, safety, and efficacy.” The guidance stresses that a Quality Agreement is not a substitute for compliance with CGMP requirements by either party and that the owner o...